Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Dow
Harvard Business School
Colorcon

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR SANCTURA XR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Sanctura Xr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00863551 ↗ Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial Completed Allergan Phase 4 2009-04-01 This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
NCT00986401 ↗ Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects Completed Allergan Phase 1 2009-10-01 The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
NCT01089751 ↗ Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily Completed Allergan Phase 4 2010-03-01 This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sanctura Xr

Condition Name

Condition Name for Sanctura Xr
Intervention Trials
Overactive Bladder 5
Urinary Bladder Diseases 1
Urinary Bladder Overactive 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sanctura Xr
Intervention Trials
Urinary Bladder, Overactive 5
Urinary Incontinence 2
Enuresis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sanctura Xr

Trials by Country

Trials by Country for Sanctura Xr
Location Trials
United States 49
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sanctura Xr
Location Trials
California 4
Ohio 3
Pennsylvania 3
Utah 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sanctura Xr

Clinical Trial Phase

Clinical Trial Phase for Sanctura Xr
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sanctura Xr
Clinical Trial Phase Trials
Completed 7
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sanctura Xr

Sponsor Name

Sponsor Name for Sanctura Xr
Sponsor Trials
Allergan 4
Astellas Scientific & Medical Affairs, Inc. 1
Karuna Pharmaceuticals 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sanctura Xr
Sponsor Trials
Industry 7
NIH 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.